Drugs / ITX 5061
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT01560468 | Mar 2012 → Apr 2018 | hepatitis C virus infection | Schiano, Thomas D., MD | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT01292824 | Feb 2011 → Jan 2013 | hepatitis C virus infection | University of Birmingham | Completed | No outcome recorded |
| Phase 1 | NCT01165359 | Sep 2010 → Feb 2012 | hepatitis C virus infection | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00606749 | Nov 2007 → Jun 2008 | pemphigus vulgaris | Kemia, Inc | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ITX5061 | “Safety and antiviral activity of the HCV entry inhibitor ITX5061 in treatment-naive HCV-infected adults: a randomized, double-blind, phase 1b study.” PMID 24041792 ↗ Sep 20134“ITX5061 is a scavenger receptor class B type I antagonist that blocks HCV entry and infection in vitro.” PMID 26437376 ↗ Mar 2016 |
| Known as | KC706 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00606749 ↗ |
| Action | Inhibit | “MAP kinase p38 alpha inhibitor” CHEMBL1208829 ↗1“HCV Entry Inhibitor ITX 5061” NCT01165359 ↗ |
| Modality | Small molecule | — CHEMBL1208829 ↗ |
| Route | Oral | “300 mg given orally beginning at the time of liver transplantation and for 1 week post-transplant followed by 150 mg orally for an additional 21 days.” NCT01560468 ↗ |
| Target | MAPK14 | “MAP kinase p38 alpha inhibitor” CHEMBL1208829 ↗ |